Literature DB >> 33629147

Splenic non-infarction volume determines a clinically significant hepatic venous pressure gradient response to partial splenic embolization in patients with cirrhosis and hypersplenism.

Tsuyoshi Ishikawa1, Ryo Sasaki2, Tatsuro Nishimura2, Takashi Matsuda2, Takuya Iwamoto2, Issei Saeki2, Isao Hidaka2, Taro Takami2, Isao Sakaida2.   

Abstract

BACKGROUND: This study aimed to investigate changes in the hepatic venous pressure gradient (HVPG) by partial splenic embolization (PSE) and to identify the determinants of a clinically meaningful postoperative HVPG reduction.
METHODS: Sixty-eight patients with cirrhosis and hypersplenism who underwent PSE at our department between September 2007 and June 2020 were included. The HVPG was evaluated pre- and immediately post-PSE. The patients were divided into three groups according to their preprocedural HVPG: low-HVPG (< 10 mmHg, n = 22), intermediate-HVPG (10 mmHg ≤ HVPG < 16 mmHg, n = 33), and high-HVPG (≥ 16 mmHg, n = 13).
RESULTS: Overall, PSE significantly reduced HVPG from 12.2 ± 4.0 to 9.4 ± 3.6 mmHg (p < 0.01) with a relative decrease of 22.2 ± 20.4%. In addition, HVPG reductions were 19.4 ± 28.7%, 24.0 ± 15.9%, and 22.5 ± 13.3% in the low-, intermediate-, and high-HVPG groups, respectively, indicating no significant difference in HVPG reduction between the groups. An HVPG decrease of ≥ 20% from the baseline, defined in this study as a clinically significant HVPG response to PSE, was achieved in 55.9% of all patients. Multivariate logistic regression and receiver operating characteristic curve analyses identified splenic non-infarction volume as an independent determinant of a 20% decrease in HVPG (p < 0.05), with a cut-off of 139.2 cm3 (sensitivity, 76.3%; specificity, 60.0%; p < 0.05).
CONCLUSIONS: The splenic non-infarction volume, namely the residual functional spleen volume, independently determines a clinically significant HVPG response to PSE in patients with cirrhosis and hypersplenism.

Entities:  

Keywords:  Hepatic venous pressure gradient; Hypersplenism; Liver cirrhosis; Partial splenic embolization; Splenic non-infarction volume

Year:  2021        PMID: 33629147     DOI: 10.1007/s00535-021-01762-7

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  8 in total

1.  Normal splenic volume in adults by computed tomography.

Authors:  Junichi Kaneko; Yasuhiko Sugawara; Yuichi Matsui; Takao Ohkubo; Masatoshi Makuuchi
Journal:  Hepatogastroenterology       Date:  2002 Nov-Dec

2.  Short-term portal hemodynamic effects of partial splenic embolization for hypersplenism.

Authors:  Fumio Chikamori; Nobutoshi Kuniyoshi; Takahiko Kawashima; Yasuhiro Takase
Journal:  Hepatogastroenterology       Date:  2007-09

3.  Splenomegaly and variceal bleeding--hemodynamic basis and treatment implications.

Authors:  R J Gusberg; S M Peterec; B E Sumpio; G H Meier
Journal:  Hepatogastroenterology       Date:  1994-12

4.  Partial spleen embolization reduces the risk of portal hypertension-induced upper gastrointestinal bleeding in patients not eligible for TIPS implantation.

Authors:  Matthias Buechter; Alisan Kahraman; Paul Manka; Guido Gerken; Alexander Dechêne; Ali Canbay; Axel Wetter; Lale Umutlu; Jens M Theysohn
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

Review 5.  Beta-blockers in cirrhosis: Evidence-based indications and limitations.

Authors:  Susana G Rodrigues; Yuly P Mendoza; Jaime Bosch
Journal:  JHEP Rep       Date:  2019-12-20

Review 6.  Risk of rupture of an aortorenal vein graft aneurysm after the surgical repair of Takayasu arteritis-induced right renal artery stenosis: A case report and a literature review.

Authors:  Xiyang Chen; Bin Huang; Ding Yuan; Yi Yang; Jichun Zhao
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

7.  Utility of minimally invasive measurement of hepatic venous pressure gradient via the peripheral antecubital vein.

Authors:  Akira Yamamoto; Norifumi Kawada; Atsushi Jogo; Kazuki Murai; Kohei Kotani; Ken Kageyama; Shinichi Hamamoto; Etsuji Sohgawa; Sawako Uchida-Kobayashi; Masaru Enomoto; Akihiro Tamori; Yukio Miki
Journal:  Gut       Date:  2020-08-18       Impact factor: 23.059

8.  Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.

Authors:  Fumiaki Watanabe; Koichi Suzuki; Sawako Tamaki; Iku Abe; Yuhei Endo; Yuji Takayama; Hideki Ishikawa; Nao Kakizawa; Masaaki Saito; Kazushige Futsuhara; Hiroshi Noda; Fumio Konishi; Toshiki Rikiyama
Journal:  PLoS One       Date:  2019-12-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.